Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

USP Update

Final Standards for Allergen Extract Compounding under USP Chapter 797 The long-awaited new USP Chapter…

read more

Impact OF 2019 Physician Fee Schedule on Allergy and Sinus Services

Specialty Impact The conversion factor for 2019 will be $36.0391 and remains essentially flat.  The changes…

read more

Your AAOA at the AMA

I want to urge you to consider membership in the AMA because your membership in…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

12/01/19: Research Grant Cycle
Learn more

04/01/20: Fellow Exam Application Deadline
Learn more

06/01/20: Research Grant Cycle
Learn more

06/01/20: Call For Scientific Abstracts Deadline
Watch Your Email

06/26/20: Membership Application Deadline to be eligible for AAOA Member rate for the 2020 Basic Course

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more

EDUCATION

New Orleans: Should I Stay or Should I Go?

Much like the Clash song lyrics, many of you will flip through this AAOA Today issue trying to assess whether it is worth the cost to get on a plane to participate in the AAOA’s Annual Meeting. We recognize you have lots of CME options, some are even competing with our meeting in New Orleans. Read More

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Learn More

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Learn More and Register

2020 Basic Course in Allergy & Immunology
July 9-11 | Orlando, FL
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

Off to College: Tips for Managing Allergies

Heading to college is an exciting time. What are the best ways for students to avoid exacerbation of their symptoms as they enter the hallowed halls of higher learning?

Read More

College Allergy Symptoms Treatment Back to Shcool

News and Updates

New Orleans: Should I Stay or Should I Go?

Much like the Clash song lyrics, many of you will flip through this AAOA Today…

read more

International Forum of Allergy & Rhinology Top Articles 2018-2019

Read top articles published in the International Forum of Allergy & Rhinology 2018-2019. Most Cited International Consensus…

read more

CEO Update – Re·im·ag·ine

re·im·ag·ineverb reinterpret (an event, work of art, etc) imaginatively; rethink Reimagined, Reinvented, Reinvigorated….these are all…

read more

Menu

EpiPen Shortage Update

FDA has a drug shortage database which includes reasons for and updates on drug shortages. Today the database read, “Meridian Medical Technologies, a subsidiary of Pfizer that manufactures EpiPen® and the authorized generic version, continues to experience manufacturing constraints. Currently, supplies will vary from pharmacy to pharmacy. Mylan, the distributor, is expediting shipments to wholesalers upon receipt from Pfizer. Patients who are experiencing difficulty accessing product should continue to contact Mylan Customer Relations at 800-796-9526 for assistance in locating alternative pharmacies.”

Earlier this month, Mylan recently released a statement about the Pfizer company’s interruptions in the production of EpiPen®. Due to the manufacturing delay there is a shortage in the EpiPen® (epinephrine injection, USP) (0.3 mg) and the EpiPen Jr® (epinephrine injection, USP) (0.15 mg) Auto-Injectors.

Pfizer’s statement is here.

Possible reasons for the shortage may include a spike in sales during the back-to-school season. Schools have reported “stocking up” on EpiPens to prepare for the school year. Additionally, on August 16th 2018, the first generic version of EpiPen, developed by Teva Pharmaceuticals, was approved. The company has not issued a launch date and it may not launch soon enough to assist families currently searching for supply.